US 12,138,419 B2
Perfusion system
Subhas Balaram Bhowmick, Baroda (IN); Prashant Kane, Baroda (IN); Samarth Kumar, Baroda (IN); and Kirti Ganorkar, Baroda (IN)
Assigned to Sun Pharmaceutical Industries Ltd., Mumbai (IN)
Filed by Sun Pharmaceutical Industries Ltd., Mumbai (IN)
Filed on Nov. 21, 2022, as Appl. No. 18/057,595.
Application 18/057,595 is a continuation of application No. 16/075,791, granted, now 11,554,207, previously published as PCT/IN2017/050055, filed on Feb. 9, 2017.
Claims priority of application No. 201621004576 (IN), filed on Feb. 9, 2016.
Prior Publication US 2023/0158226 A1, May 25, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 5/14 (2006.01); A61K 9/00 (2006.01); A61M 5/168 (2006.01)
CPC A61M 5/14 (2013.01) [A61K 9/0019 (2013.01); A61M 5/1407 (2013.01); A61M 5/16827 (2013.01); A61M 2205/6009 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A perfusion system for direct administration of a dose of irinotecan or a pharmaceutically acceptable salt thereof to any patient in a patient population in need thereof, the dose calculated according to a patient parameter, wherein the parameter varies over a range in the patient population, said system comprising:
a plurality of perfusion containers comprising:
a first set of perfusion containers consisting essentially of a first ready-to-infuse, aqueous perfusion solution of irinotecan or a pharmaceutically acceptable salt thereof at a first concentration, each perfusion container of the first set having only one outlet for withdrawal of the aqueous perfusion solution therefrom during direct administration to a patient; and
a second set of top-up perfusion containers, each top-up perfusion container of the second set consisting essentially of a second ready-to-infuse, aqueous perfusion solution of irinotecan or a pharmaceutically acceptable salt thereof at a second concentration, each top-up perfusion container of the second set having only one outlet for withdrawal of the aqueous perfusion solution therefrom during direct administration to a patient; and
instructions for selecting one or more containers from the first set of perfusion containers and, if required, one or more top-up perfusion containers from the second set for directly administering a dose of irinotecan or a pharmaceutically acceptable salt thereof to a patient from the patient population based upon the calculated dose for the patient, wherein
the perfusion system is to be used on any patient in the patient population regardless of the calculated dose, and
the aqueous perfusion solutions contained within the plurality of perfusion containers are to be directly administered to the patient without any manipulation of the aqueous perfusion solutions prior to said administration.